| Literature DB >> 19030195 |
Constantine-Iosif Fotiadis1, Christos-Nikolaou Stoidis, Basileios-Georgiou Spyropoulos, Eleftherios-Dimitriou Zografos.
Abstract
Colorectal cancer is the third most common form of cancer. Current treatments are all associated with a high risk of complications and a low success rate. Recently, synbiotics have been proposed as a new preventive and therapeutic option. There is no direct experimental evidence for cancer suppression in humans as a result of the consumption of pro-, pre- or synbiotics. However, there is a wealth of evidence emerging from laboratory studies. The mechanisms by which pro-, pre- and synbiotics may inhibit colon cancer are now beginning to be understood and will be addressed in the present review.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19030195 PMCID: PMC2773329 DOI: 10.3748/wjg.14.6453
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742